Large study points to benefits - and risks - of GLP-1 drugs
People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer's, but an increase in some other conditions like kidney stones, low blood pressure, arthritis and joint pain, and pancreatitis.
In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver failure, lung failure, cardiac arrest, aspiration pneumonia and shock.
Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...
For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.
News Medical on MSN1d
Researchers create an atlas of health associations for GLP-1 receptor agonistsInsights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback